WHAT WE CLAIM

1. A compound of formula (I)



(I)

Wherein

A is N or C,

B is a group selected from among the group consisting of

a 5-7-membered monocyclic heterocyclyl containing 1 or 2 N-atoms,

a 6-membered bicyclic heterocyclyl containing 1 N-atom,

a 7-11 membered bicyclic heterocyclyl containing 2 N-atoms,

a 7-membered bicyclic heterocyclyl containing 1 N-atom and 1 O-atom,

a 6-membered monocyclic heterocyclyl containing 1 N-atom and 1 heteroatom selected from the group consisting of O and S,

a 9-membered bicyclic heterocyclyl containing 3 heteroatoms, 2 of which are N and the other is O,

a 9-membered bicyclic heterocyclyl containing 1 N-atom and 1 S-atom,

a 10-membered bicyclic heterocyclyl containing 3 N-atoms, 2 of which are substituted with C_{1-6}-alkyl,

phenyl,

a 9-membered bicyclic heteroaryl containing 3 N-atoms,

-C_{1-4}-alkylene-pyrimidine, **and**

-C_{1-4}-alkylene-O-C_{1-3}-alkyl;

D is a group selected from among the group consisting of

a 9-membered bicyclic heteroaryl containing 2 N-atoms,

a 10-membered bicyclic heteroaryl containing 1 N-atom, **and**

benzodioxole;

R^1 is selected from among the group consisting of -H, -C_{1-6}-alkyl, -CF_3 , -C_{2-6}-alkynyl, -O-C_{1-6}-alkyl **and** halogen;

R^2 is selected from among the group consisting of -H, -C_{1-6}-alkyl, -C_{1-6}-alkylene-OH, -C(O)OH, -C(O)O-C_{1-6}-alkyl **and** -pyrazolyl-C_{1-6}-alkyl;

R^3 is -H **or** -C_{1-6}-alkyl;

R^4 is selected from among the group consisting of -H, -C_{1-3}-alkyl, -NH_2, -NHC_{1-3}-alkyl **and** $N(C_{1-3}\text{-alkyl})_2$;

R^5 is absent **or** is selected from among the group consisting of -H, -C_{1-6}-alkyl, -$S(O_2)$-C_{1-6}-alkyl, -NH-$S(O_2)$-C_{1-6}-alkyl, =O, -C(O)-C_{1-6}-alkyl, -C(O)H, -C(O)OH, -$C(O)NH_2$, -C(O)O-C_{1-6}-alkyl, -$NR^{5.1}R^{5.2}$, -C_{1-6}-alkylene-C(O)OH, -$S(O_2)$-NH_2, -pyrolidin-2-one-1-yl, -tetrazolyl, **and** a 5-membered heteroaryl with 1 or 2 heteroatoms selected from the group consisting of N and O, substituted with $R^{5.3}$;

$R^{5.1}$ is selected from among the group consisting of -H, -C_{1-6}-alkyl, -C(O)-C_{1-6}-alkyl **and** -C_{1-6}-alkylene-O-C_{1-6}-alkyl;

$R^{5.2}$ is selected from among the group consisting of -H, -C_{1-6}-alkyl, -C(O)-C_{1-6}-alkyl, -C_{1-6}-alkylene-O-C_{1-6}-alkyl **and** -C_{1-6}-alkylene-$R^{5.3}$;

$R^{5.3}$ is selected from among the group consisting of -H, -C_{1-6}-alkyl **and** a 6-membered heteroaryl with 1 or 2 heteroatoms selected from a group consisting of N and O;

R^6 is absent **or** is selected from among the group consisting of -H, -C_{1-6}-alkyl, =O **and** -C(O)OH;

or a salt thereof.

2. A compound according to claim 1, wherein

R^1 is selected from among the group consisting of -C_{1-6}-alkyl, -CF_3, -O-C_{1-6}-alkyl **and** halogen;

R^4 is -H **or** -C_{1-3}-alkyl;

or a salt thereof.

3. A compound according to any one of claims 1-2, wherein

D is selected from among the group consisting of



,


,


,


,


,


and


;

R[1] is selected from among the group consisting of -C_{1-6}-alkyl, -CF_3, -O-C_{1-6}-alkyl, -Br **and** -Cl;

R[2] is -H;

R[3] is -H;

or a salt thereof.

4. A compound according to any one of claims 1-3, wherein

D is selected from among the group consisting of



,


,


,


,


,


,


and


;

or a salt thereof.

5. A compound according to any one of claims 1-4, wherein

D is selected from among the group consisting of



,


,


and


;

or a salt thereof.

6. A compound according to any one of claims 1-5, wherein

R^5 is selected from among the group consisting of -H, -C_{1-6}-alkyl, -$S(O_2)$-C_{1-6}-alkyl, =O, -C(O)H, -$C(O)NH_2$, -C(O)OH, -C(O)O-C_{1-6}-alkyl, -$NR^{5.1}R^{5.2}$ **and** a 5-membered heteroaryl with 1 or 2 heteroatoms selected from a group consisting of N and O, substituted with $R^{5.3}$;

$R^{5.1}$ is selected from among the group consisting of -H, -C_{1-6}-alkyl, -C(O)-C_{1-6}-alkyl **and** -C_{1-6}-alkylene-O-C_{1-6}-alkyl:

$R^{5.2}$ is selected from among the group consisting of -H, -C_{1-6}-alkyl, -C(O)-C_{1-6}-alkyl, -C_{1-6}-alkylene-O-C_{1-6}-alkyl and -C_{1-6}-alkyl-$R^{5.3}$;

$R^{5.3}$ is -H **or** -C_{1-6}-alkyl;

or a salt thereof.

7. A compound according to any one of claims 1-6, wherein **B** is selected from among the group consisting of



,


,


,


,


,



,


,


,


,


,



,


,


,


,


,


,



,


,


and


;

or a salt thereof.

8. A compound according to any one of claims 1-7, wherein **B** is selected from among the group consisting of



or a salt thereof.

9. A compound according to any one of claims 1-8, wherein **B** is selected from among the group consisting of





and ;

or a salt thereof.

10. A compound according to any one of claims 1-9, selected from the group consisting of



,



,


,

,

,

,

,

,



,





and ;

or a pharmaceutically acceptable salt thereof.

11. A compound according to any one of the claims 1-10 in its salt free form.

12. A compound according to any one of claims 1-11 or a pharmaceutically acceptable salt thereof for use as a medicament.

13. A compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from among the group consisting of inflammation, allergic and autoimmune diseases, infectious diseases and cancer or for use as a vaccine adjuvants.

14. A compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, wherein the compound is to be administered after radiotherapy.

15. Use of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease selected from among the group consisting of inflammation, allergic and autoimmune diseases, infectious diseases and cancer or for use as a vaccine adjuvants.

16. Use of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer, wherein the compound is to be administered after radiotherapy.

17. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

18. A medicament combination which comprises, besides one or more compounds according to one or more of claims 1 to 11, or a pharmaceutically acceptable salt thereof as further active substances a substance selected from the group consisting of cytostatic substances, cytotoxic substances, cell proliferation inhibitors, anti-angiogenic substances, steroids, viruses, immunogenic cell death inducers, cancer targeting agents, immuno-modulating agents, antibodies and nanobodies.

19. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

20. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

21. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

22. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

23. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

24. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

25. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

26. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

27. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

28. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

29. A compound having the following structure:



or a pharmaceutically acceptable salt thereof.

30. A compound having the following structure:



.

31. A compound having the following structure:



.

32. A compound having the following structure:



.

33. A compound having the following structure:



34. A compound having the following structure:



35. A compound having the following structure:



.

36. A compound having the following structure:



.

37. A compound having the following structure:



38. A compound having the following structure:



39. A compound having the following structure:



.

40. A compound having the following structure:



.

5